1652 — Fusen Pharmaceutical Co Share Price
Last trade - 00:00- HK$637.16m
- HK$968.98m
- CNY565.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.05 | ||
| Price to Tang. Book | 1.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.04 | ||
| EV to EBITDA | 22.9 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.05% | ||
| Return on Equity | -6.16% | ||
| Operating Margin | -0.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 407.39 | 486.85 | 385.66 | 491.76 | 565.61 | n/a | n/a | 4.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -54.62 | +67.77 | -55.22 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.
Directors
- Changcheng Cao CHM (62)
- Dudu Cao CEO (32)
- Zhen Li CFO (41)
- Jiancheng Fu VPR (60)
- Zhiming Cao EDR
- Yongsheng Chi EDR (57)
- Taisheng Hou EDR (56)
- Qingfen Meng EDR (54)
- Tik Man Wong SEC (40)
- Jianhang Wang NED (36)
- Kwok Tung Lee NID (52)
- Wing Chun Sze NID (42)
- Kit Wa To NID (45)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 18th, 2013
- Public Since
- July 11th, 2018
- No. of Employees
- 1,148
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 749,596,000
- Address
- Urban Industrial Zone, Xichuan County, NANYANG
- Web
- Phone
- Auditors
- KPMG
Upcoming Events for 1652
Similar to 1652
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:08 UTC, shares in Fusen Pharmaceutical Co are trading at HK$0.85. This share price information is delayed by 15 minutes.
Shares in Fusen Pharmaceutical Co last closed at HK$0.85 and the price had moved by -37.04% over the past 365 days. In terms of relative price strength the Fusen Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -34.28% over the past year.
There is no consensus recommendation for this security.
Fusen Pharmaceutical Co does not currently pay a dividend.
Fusen Pharmaceutical Co does not currently pay a dividend.
Fusen Pharmaceutical Co does not currently pay a dividend.
To buy shares in Fusen Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.85, shares in Fusen Pharmaceutical Co had a market capitalisation of HK$637.16m.
Here are the trading details for Fusen Pharmaceutical Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1652
Based on an overall assessment of its quality, value and momentum Fusen Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusen Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -48.05%.
As of the last closing price of HK$0.85, shares in Fusen Pharmaceutical Co were trading -36.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fusen Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fusen Pharmaceutical Co's management team is headed by:
- Changcheng Cao - CHM
- Dudu Cao - CEO
- Zhen Li - CFO
- Jiancheng Fu - VPR
- Zhiming Cao - EDR
- Yongsheng Chi - EDR
- Taisheng Hou - EDR
- Qingfen Meng - EDR
- Tik Man Wong - SEC
- Jianhang Wang - NED
- Kwok Tung Lee - NID
- Wing Chun Sze - NID
- Kit Wa To - NID